Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.

Conditions

Chronic Kidney Disease Stage 2
Chronic Kidney Disease Stage 3
Metabolic Dysfunction-Associated Steatohepatitis

Interventions

DRUG: Vonafexor low dose
DRUG: Vonafexor high dose

Sponsor

Enyo Pharma